PT  - JOURNAL ARTICLE
AU  - Lehrer, Steven
AU  - Rheinstein, Peter H.
TI  - Association of Kallikrein Related Peptidase 3 (KLK3) Gene with Dermatophytosis in the UK Biobank cohort
AID  - 10.1101/2022.10.09.22280866
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.10.09.22280866
4099  - http://medrxiv.org/content/early/2022/10/10/2022.10.09.22280866.short
4100  - http://medrxiv.org/content/early/2022/10/10/2022.10.09.22280866.full
AB  - In a previous genome wide association study (GWAS) of UK Biobank (UKB) data, we identified one susceptibility locus, Tubulointerstitial Nephritis Antigen (TINAG), with genome wide significance for dermatophytosis. We used genotype calls from file UKB22418. These data are derived directly from Affymetrix DNA microarrays but are missing many genotype calls. Using computationally efficient approaches, UKB has entered imputed genotypes into a second dataset, UKB22828, increasing the number of testable variants by over 100-fold to 96 million variants. In the current study, we used UKB imputed genotypes in UKB22828 to identify dermatophytosis susceptibility loci.Methods To identify cases of dermatophytosis, we used ICD10 code B35, which covers Tinea barbae, Tinea capitis, Tinea unguium, Tinea manuum, Tinea pedis, Tinea corporis, Tinea imbricata, Tinea cruris, other dermatophytoses, and dermatophytosis, unspecified. We used PLINK, a whole-genome association analysis toolset, to analyze the UKB22828 chromosome files.Results GWAS summary (Manhattan) plot of the meta-analysis association statistics highlighted two susceptibility loci, TINAG and Kallikrein Related Peptidase 3 (KLK3), with genome wide significance for dermatophytosis.Conclusion KLK3 may be a dermatophytosis susceptibility gene. KLK3 could affect risk of dermatophytosis, since kallikreins are necessary for normal homeostasis of the skin.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study received no direct funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:UK BiobankI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData in this study may be obtained from UK Biobank after approval of a formal application. https://www.ukbiobank.ac.uk/